Despite the increased number of treatment options, patient access to those multiple myeloma drug options has not changed much.

Multiple myeloma remains an incurable disease, but in the past, survival rates were very low due to limited treatment options.

In recent years, however, innovative treatment options such as monoclonal antibodies, CAR-T therapies, and bispecific antibodies have diversified the treatment options, improving survival.

In fact, over the past 20 years, the five-year survival rate for multiple myeloma patients has increased from 29.8% in 2001-2005 to about 50.1% in 2017-2021. However, this is still less than the 60% survival rate found in developed count